Stay updated with breaking news from Andrew selfridge. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Share this article Share this article SAN DIEGO, Dec. 11, 2020 /PRNewswire/ Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that data from the Phase 2b ADVISE trial evaluating the safety and efficacy of etrasimod, a highly selective, once-daily, oral sphingosine 1-phosphate (S1P) receptor modulator, in participants with moderate-to-severe atopic dermatitis (AD), will be presented at the Revolutionizing Atopic Dermatitis (RAD) 2020 Virtual Conference. I am pleased to present the topline results from the ADVISE Phase 2 trial which support the rationale for etrasimod as a potential oral, once-daily therapy with a novel mechanism of action for the treatment of atopic dermatitis. I look forward to seeing the advancement of etrasimod to the next phase of clinical development, stated Robert Bissonnette, MD, FRCPC, Founder and CEO, Innovaderm Research. There is a significant unmet clinical need for the development of novel oral therapeutic options for atopic de ....